Floatz logo

mt027

Malignant Pleural Effusion

Suzhou Maximum Bio-tech Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Malignant Pleural Effusion cohort.

Asset / SponsorPhaseRating
Carboplatin
University of Washington
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Chinese PLA General Hospital
Phase 3BB
Docetaxel
University of Washington
Phase 2B
Bortezomib
National Cancer Institute (NCI)
Phase 2B
Imatinib
University of Washington
Phase 2B

View all 19 →

Same molecule, other indications

mt027 is also rated in:

cancerDormant
CC
Indicative ·
45 / 100
View asset →
malignant pleural mesotheliomaDormant
CC
Indicative ·
43 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →